Briefs

by Marshall Kirkpatrick / October 16, 2008

International recommendation technology provider Strands has announced the five finalists in the Strands $100K Call for Recommender Start-Ups. From music to video to pharmaceutical drug development recommendations, these plucky startups from all around the world will now present at the Association for Computing Machinery's Recommender Systems 2008 conference in Switzerland and one will be offered a $100k investment from Strands.

Gravity R&D is a four person team from Budapest University of Technology in Hungary. Strands says the team has built a "magic button" that "provides TV viewers instant personalized entertainment at any given time with relevant program tips instantaneously on customer demand.

Sentimetrix is another four person team, this one from the University of Maryland Institute for Advanced Computer Sciences. This startup analyzes text content around the web and "has automated sentiment extraction/analysis/scoring, the ability to find and quantify opinions in text." If this kind of technology is of interest to you, see also our review yesterday of the new BooRah API.

iletken is a mysterious project built by four Turkish college students at Koc University. It balances personal and social behavior to recommend advertisements "based on relevance."

Reccoon is a stealth project built by Peter Tegelaar and Dominiek ter Heide in the Netherlands. Ter Heide also worked on the Japanese social learning platform iKnow, which launched an API yesterday. Recoon appears to use the iPhone's GPS, user attention data like Last.fm listening history and the GeoNames reverse lookup API to notify you when you're near the location of an event you might like to participate in.

Commendo is a four person team from two universities in Austria. Team Commendo is both the Grand Prize winner and in first place for the Progress Prize in the Netflix Prize leaderboard.

Strands describes Commendo like this: "Commendo uses recommendation technologies to optimize the drug design process in the pharmaceutical industry, including speeding up drug development and the minimization of adverse drug reactions."

Read more.